Clinical Trials Logo

Myalgia clinical trials

View clinical trials related to Myalgia.

Filter by:

NCT ID: NCT03612843 Completed - Knee Osteoarthritis Clinical Trials

Adverse Events in Dry Needling

Start date: August 1, 2018
Phase:
Study type: Observational

The purpose of this prospective cohort survey study is to further explore the incidence of adverse events with dry needling by physical therapists - as well as any differences or similarities between patient-reported vs therapist-reported incidence of AEs.

NCT ID: NCT03573219 Completed - Clinical trials for Musculoskeletal Pain

A New Experimental Model of Transient and Short-lasting Muscle Pain in Humans Based on Diathermy

Start date: February 19, 2018
Phase: N/A
Study type: Interventional

This study evaluates the use of short-wave diathermy (SWD) as an novel experimental model to induce transient and intensity-controlled muscle pain by heating muscle tissue.

NCT ID: NCT03510806 Completed - Clinical trials for Post-exercise Muscle Soreness

Nutritional Supplements for Exercise Recovery

Start date: March 20, 2018
Phase: N/A
Study type: Interventional

This study will examine the effects of nutritional supplement on post-exercise muscle soreness as well as recovery of muscle strength and function.

NCT ID: NCT03476044 Completed - Clinical trials for Postoperative Myalgia

Effect of Selenium on Succinylcholine-Induced POM

Start date: June 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

For more than 60 years, succinylcholine is still being administered as the selective relaxant for rapid sequence intubation by anesthesiologists in many countries. It has been shown to possess unique features such as low cost, fast-acting, short half-life, safe metabolites, and causing excellent muscle relaxation for intubation. However, it has many side effects as well. Postoperative myalgia (POM), with an incidence rate of about 41%-92%, is one of the most common side effects of this drug and can take several days to cause significant discomfort in patients. However, its effect is felt more in the throat, neck, shoulder, and abdominal muscles and is common among patients with outpatient surgery. Due to its unknown real context of pathogenesis and in an effort to reduce the incidence and severity of succinylcholine-induced myalgia, various medications including non-depolarizing muscle relaxants, benzodiazepines, magnesium sulfate, opioids, gabapentin, pregabalin and nonsteroidal anti-inflammatory drugs have been tested, with varying degrees of success. Free radicals are created as a consequence of ATP (adenosine triphosphate) production by the mitochondria. These by-products are generally reactive oxygen species (ROS) as well as reactive nitrogen species (RNS) that result from the cellular redox process. These species play a dual role as both toxic and beneficial compounds. The delicate balance between their two antagonistic effects is clearly an important aspect of life. At low or moderate levels, ROS and RNS exert beneficial effects on cellular responses and immune function. At high concentrations, they generate oxidative stress, a deleterious process that can damage all cell structures. Muscle injuries might lead to the production of free radicals and further cellular damage, triggered by lipid peroxidation and protein oxidation. Peroxidation of membrane lipids leads to loss of membrane fluidity and elasticity, impaired cellular functioning, and even cell rupture. The various direct products of lipid peroxidation, such as malondialdehyde (MDA), isoprostanes, and 4-hydroxynonenal are considered among the most important biomarkers of oxidative stress in tissues. Malondialdehyde is a reactive carbonyl compound and is both mutagenic and carcinogenic. It reacts with DNA to form DNA adducts that are believed to contribute significantly to cancers linked to lifestyle and dietary factors. Protein oxidation can cause fragmentation at amino acid residues, formation of protein-protein cross-linkages, and oxidation of the protein backbone which ultimately leads to loss of function. Damaged proteins affect intracellular pathways and are contributing factors to different disorders and diseases. Protein carbonyl (CO) groups are produced on protein side chains during oxidation. High levels of protein CO groups have been observed in rheumatoid arthritis, Alzheimer's disease, diabetes, sepsis and chronic renal failure. Selenium is a well-recognized antioxidant which act s as a cofactor of antioxidant enzymes. This essential element helps protect the body against free radicals causing damage to the cells. Substantial evidence suggests that free radical production leads to increased oxygen uptake over time. The indirect though significant impact of selenium supplements is to protect the cells against oxidative stress and free radical production. Nature-made selenium contains 200 mg of this element with a natural origin, high absorption capacity, and prolonged retention. Selenium exerts its antioxidant effects through glutathione peroxidase. Glutathione peroxidase is an enzyme containing four selenium-cofactors that catalyze the breakdown of hydrogen peroxide and organic hydroperoxides. There are at least four different glutathione peroxidase isozymes in animals. Glutathione peroxidase 1 is the most abundant and is a very efficient scavenger of hydrogen peroxide, while glutathione peroxidase 4 is most active with lipid hydroperoxides. The glutathione S-transferases show high activity with lipid peroxides. These enzymes are at particularly high levels in the liver and serve in detoxification metabolism.

NCT ID: NCT03417323 Completed - Clinical trials for Repeated Bout Effect of WB-EMS

Effects of Compression Wear on Muscle Soreness

COMDOME
Start date: December 10, 2017
Phase: N/A
Study type: Interventional

The study address two main topics: 1. The effect of compression garment on whole-body electromyostimulation (WB-EMS) induced muscle soreness in young adults 2. The repeated bout effect of one intense session of WB-EMS as determined by various regeneration parameters

NCT ID: NCT03371888 Completed - Clinical trials for Temporomandibular Disorder

The Platelet-Rich Plasma in the Therapy of Temporomandibular Disorders

PRP/TMD
Start date: December 7, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The Platelet-Rich Plasma intramuscular injections into the masseter and temporalis muscle were performed to reduce painful temporomandibular disorder symptoms,such as myalgia, myofascial pain and myofascial pain with referrals. Patients(n=120) were randomly divided into two groups: experimental(n=60) and control group(n=60). In controls injections with 0,9% NaCl were performed. Pain intensity was measured with NPRS (numeriic pain rating scale, 0= no pain, 11= the worst pain that one can imagine) before(0 day), during(10 day) and after(20 day) the therapy with PRP injections.

NCT ID: NCT03354624 Completed - Exercise Clinical Trials

Cortical Neuroplasticity by Muscle Pain of Pain-induced Plasticity

Start date: November 26, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the sensory-motor cortical excitability response to delayed onset muscle soreness (DOMS) on Extensor Carpi Radialis (ECR) muscle during muscle hyperalgesia provoked by nerve growth factor (NGF).

NCT ID: NCT03263884 Completed - Pain Relief Clinical Trials

Repetitive Transcranial Magnetic Stimulation and the Development of Ongoing Muscle Pain

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The main purpose of the study is to assess the mechanisms of repeated sessions of repetitive trancranial magnetic stimulation (rTMS) applied on left dorsolateral prefrontal cortex on the development of pain in a prolonged muscle pain model.

NCT ID: NCT03228992 Completed - Muscle Soreness Clinical Trials

Ibuprofen Versus Placebo For Muscle Soreness

Start date: April 10, 2017
Phase: Phase 4
Study type: Interventional

The study will assess the sensitivity of the Delayed Onset Muscle Soreness Model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.

NCT ID: NCT03223519 Completed - Clinical trials for Delayed Onset Muscle Soreness, DOMS

COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS)

Start date: July 12, 2017
Phase: Phase 2
Study type: Interventional

The study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of Comboprofen (Ibuprofen + Magnesium + Vitamin C) compared to placebo, Ibuprofen, Magnesium and Vitamin C monotherapies in the treatment of Delayed Onset Muscle Soreness (DOMS).